Dianthus Therapeutics, Inc.

How big is Dianthus Therapeutics, Inc.?

As of Jun 18, Dianthus Therapeutics, Inc. has a market capitalization of 555.40 million, with net sales of 6.52 million and a net profit of -100.73 million over the last four quarters. The company's shareholder's funds are 352.48 million, and total assets amount to 374.24 million.

Market Cap: As of Jun 18, Dianthus Therapeutics, Inc. has a market capitalization of 555.40 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 6.52 million and a net profit of -100.73 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 352.48 million, while total assets were reported at 374.24 million.

What does Dianthus Therapeutics, Inc. do?

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company developing curative treatments for autoimmune diseases, blood cancers, and genetic diseases. As of March 2025, it has a market cap of $555.40 million, with net sales of $1 million and a net loss of $30 million.

Overview:<BR>Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing medicines aimed at providing curative treatments for autoimmune diseases, blood cancers, and genetic diseases within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -30 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 555.40 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.80 <BR>Return on Equity: -30.65% <BR>Price to Book: 1.69<BR><BR>Contact Details:<BR>Address: 100 Technology Sq Fl 5, CAMBRIDGE MA : 02139-3585 <BR>Tel: 1 857 2012700 <BR>Fax: 1 302 6555049 <BR>Website: https://www.magentatx.com/

Should I buy, sell or hold Dianthus Therapeutics, Inc.?

Who are in the management team of Dianthus Therapeutics, Inc.?

As of March 2022, the management team of Dianthus Therapeutics, Inc. includes Independent Chairman Mr. Michael Bonney, President and CEO Mr. Jason Gardner, and several Independent Directors: Mr. Jeffrey Albers, Dr. Bruce Booth, Mr. Alexis Borisy, Dr. Blake Byers, and Dr. Thomas Daniel. They are responsible for guiding the company's strategic direction and operations.

As of March 2022, the management team of Dianthus Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Michael Bonney, who serves as the Independent Chairman of the Board.<BR>- Mr. Jason Gardner, who is the President, Chief Executive Officer, Co-Founder, and Director.<BR>- Additionally, the board includes several Independent Directors: Mr. Jeffrey Albers, Dr. Bruce Booth, Mr. Alexis Borisy, Dr. Blake Byers, and Dr. Thomas Daniel.<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Is Dianthus Therapeutics, Inc. overvalued or undervalued?

As of March 21, 2024, Dianthus Therapeutics, Inc. is rated as risky due to its negative earnings, high valuation ratios, and poor long-term performance, despite a recent short-term gain of 85.45%.

As of 21 March 2024, the valuation grade for Dianthus Therapeutics, Inc. has moved from does not qualify to risky, indicating increased concern regarding its financial health. The company appears to be overvalued given its negative earnings and high valuation ratios, including a Price to Book Value of 1.84, an EV to Sales ratio of 52.61, and a ROE of -30.65%. <BR><BR>In comparison to its peers, Dianthus has a significantly lower EV to EBITDA ratio of -2.94 compared to Syndax Pharmaceuticals, Inc. at -3.8242 and Rayzebio, Inc. at -46.3970, highlighting its relative weakness. Additionally, while the stock has shown strong short-term performance with a 1-month return of 85.45% compared to the S&P 500's 2.33%, its long-term performance remains concerning, with a 5-year return of -68.53% against the S&P 500's 96.61%. This suggests that despite recent gains, the overall valuation remains precarious.

Is Dianthus Therapeutics, Inc. technically bullish or bearish?

As of October 3, 2025, Dianthus Therapeutics, Inc. shows a mildly bullish trend, supported by bullish daily moving averages and weekly MACD, despite a bearish weekly RSI and mixed KST signals, with a notable 30.04% return over the past month and 2397.10% over three years.

As of 3 October 2025, the technical trend for Dianthus Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages indicate a bullish stance. However, the weekly RSI is bearish, and the weekly KST is bullish but the monthly KST is mildly bearish. Dow Theory shows a mildly bearish trend on the weekly timeframe, with no trend on the monthly. Bollinger Bands are mildly bullish on both weekly and monthly timeframes.<BR><BR>In terms of performance, the stock has returned 30.04% over the past month compared to the S&P 500's 4.15%, and a remarkable 2397.10% over the past three years against the S&P 500's 82.57%. Overall, the current stance is mildly bullish, driven primarily by the bullish daily moving averages and the weekly MACD.